|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.21 USD | -4.13% |
|
+5.37% | +11.68% |
May 23 (Reuters) - Advisers to the U.S. Food and Drug Administration on Thursday recommended for the approval of Guardant Health's blood test to detect a cancer that begins in the colon or rectum.
The panel voted seven-to-two in favor of benefits outweighing risks when using the test called Shield for colorectal cancer. (Reporting by Puyaan Singh and Leroy Leo in Bengaluru; Editing by Arun Koyyur)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 110.2 USD | -0.53% | -0.89% | 13.53B | ||
| 41.88 USD | -2.04% | -2.45% | 7.73B | ||
| 30.21 USD | -4.13% | +5.37% | 3.7B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +11.68% | 3.7B | |
| +0.37% | 2.28B | |
| -21.21% | 1.99B | |
| -23.77% | 1.6B | |
| +14.81% | 999M | |
| +18.25% | 739M | |
| -10.04% | 687M | |
| -36.12% | 461M | |
| -4.47% | 279M | |
| -16.34% | 160M |
GUARDANT HEALTH, INC. 
